In an international study co-led by UCLA, investigators found an investigational targeted therapy significantly extended overall survival for patients with previously treated metastatic pancreatic cancer and reduced the risk of death by 60% compared with standard chemotherapy in both the RAS G12 and the overall, or intent-to-treat (ITT) population, which included patients with and without identified tumor RAS mutations.

The team found patients who received the drug daraxonrasib, an investigational, first-in-class oral RAS(ON) multi-selective inhibitor designed to block active RAS signaling — one of the primary drivers of pancreatic cancer — lived a median of 13.2 months compared with 6.7 months for those who received investigator’s choice chemotherapy in the RAS G12 population.

The findings suggest a potential investigational treatment option for patients with metastatic pancreatic cancer, a disease that remains among the most lethal cancers and has limited effective therapies.